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The human genome encodes snippets of 
RNAs ranging from 21–23 nucleotides in 
length, called microRNAs (miRNAs). 
Rather than code for proteins, miRNAs 
instead sabotage the translation of 
mRNAs. miRNAs are first generated as 
longer, hairpin-like precursors in the nu-
cleus. In the cytoplasm, a collection of 
enzymes strips down the hairpins into 
their tiny and unwound final structure. 
miRNA-bound mRNAs are 
either sequestered from trans-
lation or destroyed outright—
processes known as RNA 
interference (RNAi).
Michael McManus has 
been a fan of small RNAs 
and their manipulative power 
his entire career. As a gradu-
ate student, he studied how 
small RNAs in trypanosomes guide RNA 
editing, whereby incomplete mito-
chondrial mRNAs are filled in with 
uridine residues (1, 2).
During his postdoctoral stay in Nobel 
Laureate Phillip Sharp’s laboratory at 
MIT, McManus’s work led to one of 
the first reports of RNAi activity in mam-
malian cells (3). He showed that T cell 
genes could be suppressed by a class of 
small double-stranded RNA called short 
interfering RNAs (siRNA). His next 
discovery—that synthetic miRNA hairpin 
structures could be stably introduced into 
cells via DNA vectors—gave the field a 
reliable tool for studying RNAi (4).
Now heading his own lab at the 
University of California, San Francisco, 
McManus is exploring the role of 
miRNAs during development and dis-
ease. His team has developed a mouse 
model in which the gene for the miRNA-
processing enzyme Dicer can be selec-
tively switched off (5) and a technique to 
visualize miRNA expression patterns in 
situ (6). They are now creating RNAi 
libraries that can be used to analyze gene 
function in cells and in animal models. 
McManus is also involved in collabora-
tions to understand how miRNA fail-
ures lead to diseases such as diabetes. He 
recently began a project funded by the 
Keck Foundation to create 100 different 
miRNA mouse knockouts.
FINDING THE WAY TO RNA
When did you decide that you wanted to 
be a scientist?
During my early high school years, I was 
painting a lot and creating three-dimen-
sional art and thought of making a living 
as an artist. Then, in my last year in high 
school, I realized that my second passion, 
science, was a more practical route. I 
fi  gured that, as an artist, it would’ve been 
hard for me to do molecular biology 
on the side. But as a molecular biologist, 
I could maybe do some art on the side.
Has it actually worked out that way?
I’m not doing as much art as I would 
like. But had I gone the art route, I 
defi  nitely wouldn’t have done as much 
molecular biology as I have.
How did your interest in RNA biology 
come about?
I initially thought I wanted to be a plant 
biologist and went off    to agricultural 
school at Auburn University in Alabama, 
which is where I’m from. But by my 
second year as an undergrad, I was swap-
ping courses like pomology (the study of 
pitted fruits) for plant genetics and bio-
chemistry. I remember sitting in the dean’s 
offi   ce trying desperately to get out of 
taking courses like pesticide management.
So when I went off to graduate school, 
I tried out neurobiology and glycobiology 
before going to Steve Hajduk’s lab to 
study RNA editing. All the lab rotations 
were fantastic, but the RNA work thrilled 
me because I saw a lot of black boxes.
FROM EDITING TO INTERFERING
What was your Ph.D. project?
I studied how guide RNAs direct RNA 
editing—a process that’s only been seen 
so far in trypanosomes. By the end of 
the project, we had a good idea of how 
these RNA bits got anchored to the 
about-to-be-edited mRNA and guided 
its posttranscriptional processing. I dis-
covered the identity of the RNA ligase 
that stitches the edited sections of the 
mRNA together.
How did you segue from guide RNA to 
microRNA?
I was fascinated by the idea that small, 
noncoding RNAs could actually direct 
and regulate gene expression. I read a 
paper that Victor Ambros had published in 
1993 in which he described the fi  rst 
miRNA, lin-4, which regulated develop-
mental timing in C. elegans. At the time, 
everyone thought that this was an inter-
esting and peculiar oddity in worms.
As I was wrapping up in graduate 
school, it was becoming clear that bio-
logically active small RNAs could be gen-
erated from longer RNA duplexes, and 
there were some ideas in the field about 
how these RNAs were operating in plants 
and worms. But of course RNAi could 
also be occurring in mammalian cells. So 
I emailed Phil Sharp at MIT, and we had 
an interesting discussion about the topic.
Later, when I started to explore my 
postdoctoral options, my wife, who is a 
professional ballerina by training, sug-
gested that we move to Boston where 
she wanted to explore the arts scene. I 
remembered my discussions with Phil, 
who is also in Boston, and decided to go 
there to see whether RNAi occurred in 
mammalian cells.
Michael McManus wants to use small bits of RNA to end the mischief caused 
by genes gone bad.
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TRYING TO DELIVER
Apart from studying RNAi in T cells, 
you also had other projects in Phil’s lab?
After it was shown that RNAi was not 
just a worm-specifi  c phenomenon, there 
was a great interest in using RNAi in 
other models. And so there was a race to 
optimize the process of expressing siRNA 
in various cells and organisms. As the idea 
is to silence a gene to study its function, 
the constant degradation and dilution of 
siRNA is very much an irritation. 
You’ve got a battle against time and a 
small window through which to explore 
your question.
So we came up with the idea of 
short-hairpin RNAs (shRNAs) in which 
the siRNA is first stuck into the hairpin 
of an miRNA-like structure, which can 
be introduced into cells through a DNA 
vector. We could thus trick cells into 
producing specific small RNAs that 
target their own genes.
Are there other systems out there for 
RNAi delivery?
Sure. Ever since mammalian RNAi ex-
ploded into the biomedical community, 
a lot of people have developed their 
own favorite systems. RNAi delivery is a 
crucial issue because RNAi is more than 
a lab tool to study gene function. The 
potential of using it as therapy to turn 
down mutated genes has turned it into a 
multibillion dollar industry.
Some have tried small RNA delivery 
via antibodies. Another method is geared 
toward targeting viruses such as HIV. 
Lentiviruses, which can easily infect mam-
malian cells, can be turned into Trojan 
horses by including a short-hairpin RNA 
that targets HIV. The lentiviruses can be 
introduced into a person’s hematopoietic 
stem cells, which could then be put back 
into the patient. The hope is that when 
these cells divide and differentiate, they 
will reconstitute the person’s immune 
system so that all of their blood cells 
express the HIV-targeting shRNA. My 
lab at UCSF now houses a lentiviral core 
that provides the research community 
with shRNA-carrying vectors.
Others are already conducting clinical 
trials of this technology. It’s phenomenal 
that we’ve gone from mammalian RNAi 
discovery in 2001 to clinical trials by 2007. 
But I need to be reserved in my excite-
ment, because there’s a lot of groundwork 
that needs to be explored regarding the 
safety and efficacy of RNAi.
FUTURE PLANS
We know about hundreds of miRNAs, but 
what do we know about their target genes?
We recently found that one of the tar-
gets—the gene for Hox8, which controls 
limb development—actually carries an 
miRNA gene within its locus. This was 
kind of a big deal because this locus has 
been studied for a very long time and peo-
ple thought they knew all the genes that 
were in there. So the miRNA gene lurk-
ing there was a surprise. As the Hox genes 
are primarily regulated at the transcrip-
tional level, the miRNA might be acting 
as a backup regulator posttranscriptionally.
In collaboration with Mike German’s 
group, we’ve also found that a specific 
group of miRNAs turn on the genes 
that are required for the development of 
insulin-producing  β cells in the pan-
creas. Ultimately, this information might 
help in generating these cells for thera-
peutic purposes.
We are in the 
process of knocking 
out 100 different 
miRNAs in the mouse 
and seeing if any of 
the knockouts will be 
reminiscent of any 
human disease. It’s a 
very bold and ambi-
tious project that 
will make the mouse 
models available to the community and 
bring together a pipeline of investigators 
studying RNAi in various disease con-
texts. This work, which is funded by 
the Keck Foundation, has helped me 
to establish a center for noncoding 
RNAs at UCSF.
What made you choose the UCSF 
Diabetes Center for starting your own lab? 
I’m very much a basic scientist study-
ing basic molecular mechanisms and 
gene expression. I’m not an endo-
crinologist or a clinician of any kind. 
But I have always been a very interactive 
scientist. So I wanted to position myself 
in an environment where I could rub 
elbows with the people who are study-
ing various diseases, because I’d like to 
be able to translate some of my ideas 
into real-life therapeutics.
Apart from the potential for collabora-
tion, I also wanted to move here for 
my wife. San Francisco really appealed 
to us because it’s so liberal and chock 
full of artists. It seems like the perfect 
home for us.
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Each family of small RNAs uses a different strategy to 
meddle with gene expression.
“The potential 
of using [RNAi] 
as therapy to 
turn down 
mutated genes 
has turned it 
into a multibillion 
dollar industry.”